Current Update of Antispastic Drug
Article information
J Korean Med Assoc. 2007;50(2):161-169
Publication date (electronic) : 2007 January 20
doi :
https://doi.org/10.5124/jkma.2007.50.2.161
Abstract
Abstract
Spasticity is a velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyperexcitability of the stretch reflex. As one component of the upper motor neuron syndrome, spasticity remains a vexing problem for both clinicians and patients. Although several medications have been approved for clinical use in patients with spasticity, the literature has yielded no clear standard of care. The aims of this article are to review the mechanisms of spasticity, factors to consider when choosing and starting antispastic drugs in clinical settings, and the typical characteristics and effects of commonly used agents. This review will focus only on enteral medications, not neurolytic or intrathecal therapy.
Keywords: Spasticity; Drug; Mechanism; Side effect
Considering factors for antispasticity drug selection
Comparison of Mechanism, Half life, Dose, Excretion
Comparison of side effect, withdrawal symptoms, cautions
References
1. Young RR. Spasticity: a review. Neurology 1994;44:S12–20.
2. Rice GP. Pharmacotherapy of spasticity: some theoretical and practical considerations. Can J Neurol Sci 1987;14:510–512.
3. Davidoff RA. Antispasticity drugs: mechanisms of action. Ann Neurol 1985;17:107–116.
4. Zafonte R, Lombard L, Elovic E. Antispasticity medications: uses and limitations of enteral therapy. Am J Phys Med Rehabil 2004;83:S50–58.
5. Bes A, Eyssette M, Pierrot?Deseilligny E, Rohmer F, Warter JM. A multi?centre, double?blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin 1988;10:709–718.
6. Eyssette M, Rohmer F, Serratrice G, Warter JM, Boisson D. Multi?centre, double?blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin 1988;10:699–708.
7. Nance PW, Bugaresti J, Shellenberger K, Sheremata W, Mar-tinez?Arizala A. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. Neurology 1994;44(11 Suppl 9)): S44–51;discussion. :S51–52.
8. Coward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology 1994;44(11 Suppl 9)): S6–10;discussion. :S10–11.
9. Delwaide PJ, Pennisi G. Tizanidine and electrophysiologic analysis of spinal control mechanisms in humans with spasticity. Neurology 1994;44(11 Suppl 9)): S2–27;discussion. :S27–28.
10. Naftchi NE, Kirschner AK, Demeny M, Viau AT. Alterations in norepinephrine, serotonin, c?AMP, and transsynaptic induction of tyrosine hydroxylase after spinal cord transection in the rat. Neurochem Res 1981;6:1205–1216.
11. Maynard FM. Early clinical experience with clonidine in spinal spasticity. Paraplegia 1986;24:175–182.
12. Donovan WH, Carter RE, Rossi CD, Wilkerson MA. Clonidine effect on spasticity: a clinical trial. Arch Phys Med Rehabil 1988;69(3 pt 1):193–194.
13. Herman R, Mayer N, Mecomber SA. Clinical pharmaco? physiology of dantrolene sodium. Am J Phys Med 1972;51:296–311.
14. Flewellen EH, Nelson TE, Jones WP, Arens JF, Wagner DL. Dantrolene dose response in awake man: implications for management of malignant hyperthermia. Anesthesiology 1983;59:275–280.
15. Bishop B. Spasticity: its physiology and management. Part IV. Current and projected treatment procedures for spasticity. Phys Ther 1977;57:396–401.
16. Lin JP, Brown JK, Brotherstone R. Assessment of spasticity in hemiplegic cerebral palsy. II: Distal lower?limb reflex excitability and function. Dev Med Child Neurol 1994;36:290–303.
17. Little J. Spasticity and associated abnormality of muscle tone. In : DeLIsa J, ed. Rehabilitation Medicine: Principles and Practice 3rd ed.th ed. Philadelphia: Lippincott?Raven; 2006. p. 997–1013.
18. Burke D. Spasticity as an adaptation to pyramidal tract injury. Adv Neurol 1988;47:401–423.
19. Nakayama R, Yano T, Ushijima K, Abe E, Terasaki H. Effects of dantrolene on extracellular glutamate concentration and neuronal death in the rat hippocampal CA1 region subjected to transient ischemia. Anesthesiology 2002;96:705–710.
20. Francis HP, Wade DT, Turner?Stokes L, Kingswell RS, Dott CS, Coxon EA. Does reducing spasticity translate into functional benefit? An exploratory meta?analysis. J Neurol Neurosurg Psychiatry 2004;75:1547–1551.
21. Utili R, Boitnott JK, Zimmerman HJ. Dantrolene?associated hepatic injury. Incidence and character. Gastroenterology 1977;72:610–616.
22. Pinder RM, Brogden RN, Speight TM, Avery GS. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1977;13:3–23.
23. Terrence CF, Fromm GH. Complications of baclofen withdrawal. Arch Neurol 1981;38:588–589.
24. Duncan GW, Shahani BT, Young RR. An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double?blind, cross? over study. Neurology 1976;26:441–446.
25. Taricco M, Adone R, Pagliacci C, Telaro E. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst Rev 2000;2:CD001131.
26. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl 1997;6:S92–120.
27. Stahl MM, Saldeen P, Vinge E. Reversal of fetal benzodia-zepine intoxication using flumazenil. Br J Obstet Gynaecol 1993;100:185–188.
28. Nance P. Spasticity management. In : RL Braddom, ed. Physical Medicine and Rehabilitation 3rd ed.th ed. China: Saunders Elsevier; 2006. p. 651–665.
29. Roussan M, Terrence C, Fromm G. Baclofen versus diazepam for the treatment of spasticity and long?term follow?up of baclofen therapy. Pharmatherapeutica 1985;4:278–284.
30. Dunevsky A, Perel AB. Gabapentin for relief of spasticity associated with multiple sclerosis. Am J Phys Med Rehabil 1998;77:451–454.
31. Basmajian JV, Shankardass K, Russell D, Yucel V. Ketazolam treatment for spasticity: double?blind study of a new drug. Arch Phys Med Rehabil 1984;65:698–701.
32. Cendrowski W, Sobczyk W. Clonazepam, baclofen and placebo in the treatment of spasticity. Eur Neurol 1977;16:257–262.
33. Smolenski C, Muff S, Smolenski?Kautz S. A double?blind comparative trial of new muscle relaxant, tizanidine(DS 103–282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin 1981;7:374–383.
34. Medici M, Pebet M, Ciblis D. A double?blind, long?term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Curr Med Res Opin 1989;11:398–407.
35. Weingarden SI, Belen JG. Clonidine transdermal system for treatment of spasticity in spinal cord injury. Arch Phys Med Rehabil 1992;73:876–877.
36. Stewart JE, Barbeau H, Gauthier S. Modulation of locomotor patterns and spasticity with clonidine in spinal cord injured patients. Can J Neurol Sci 1991;18:321–332.
37. Dall JT, Harmon RL, Quinn CM. Use of clonidine for treatment of spasticity arising from various forms of brain injury: a case series. Brain Inj 1996;10:453–458.
38. Mandac BR, Hurvitz EA, Nelson VS. Hyperthermia associated with baclofen withdrawal and increased spasticity. Arch Phys Med Rehabil 1993;74:96–97.
39. Joynt RL, Leonard JA Jr. Dantrolene sodium suspension in treatment of spastic cerebral palsy. Dev Med Child Neurol 1980;22:755–767.
Article information Continued
Copyright © 2007 Korean Medical Association